Comparative Pharmacology
Head-to-head clinical analysis: EPANOVA versus TRAVASOL 2 75 IN DEXTROSE 5 IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EPANOVA versus TRAVASOL 2 75 IN DEXTROSE 5 IN PLASTIC CONTAINER.
EPANOVA vs TRAVASOL 2.75% IN DEXTROSE 5% IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Omega-3 fatty acids (EPA and DHA) reduce hepatic very low-density lipoprotein (VLDL) synthesis and increase triglyceride clearance from circulating VLDL particles through activation of lipoprotein lipase.
Amino acids provide substrates for protein synthesis and energy metabolism; dextrose provides caloric support.
4 g orally once daily as 4 capsules of 1 g each with food.
Intravenous infusion. Typical adult dose: 500 mL to 1000 mL per day administered at a rate not exceeding 5 mL/kg/hour, based on protein and electrolyte requirements.
None Documented
None Documented
Terminal elimination half-life approximately 89 hours (range 59–144 hr); allows weekly intramuscular dosing.
Not applicable; components are endogenous substances with rapid metabolic turnover. Exogenous amino acids have half-lives of minutes to hours, dextrose ~1-2 hours.
Primarily hepatic metabolism via omega-oxidation and subsequent conjugation; renal excretion of metabolites: ~15% unchanged in urine; biliary/fecal elimination accounts for ~85% as metabolites.
Renal: 100% of infused amino acids and dextrose are metabolized or excreted; no intact drug excretion. Biliary/fecal: negligible.
Category C
Category C
Parenteral Nutrition Solution
Parenteral Nutrition Solution